LAUSR

In the available phase 3 trial, mRNA-1273 (Moderna) COVID19 vaccine showed a high efficacy together with a good tolerability [1]. Although the trial included a fraction of people with diabetes, no specific subgroup analyses on adverse events were performed in individuals with T1D. In addition, most adverse reactions are related to the activation of local and/or systemic inflammation, which could potentially impair glucose control in T1D, thus likely contributing to vaccine hesitancy in patients with diabetes [2]. On the other hand, since diabetes is associated with a worse outcome of COVID-19 [3], vaccination is particularly recommended in patients with T1D. Aim of the present study is the assessment of the safety profile of mRNA-1273 vaccine in patients with T1D, including its effects on glucose variability in patients with interstitial glucose monitoring devices.